NeuroPace Showcases Expanding Role of Responsive Neuromodulation at ASSFN 2026
NeuroPace, a leading medical device company dedicated to improving outcomes for people living with epilepsy, is set to play a prominent role at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Annual Meeting, taking place from May 29 through June 2 in Cleveland, Ohio. The company plans to showcase the growing clinical impact of responsive neuromodulation and present emerging evidence supporting broader applications of its RNS® System for patients with drug-resistant epilepsy.
During the conference, NeuroPace will engage with neurosurgeons, epilepsy specialists, and healthcare professionals through scientific presentations, educational initiatives, technology demonstrations, and collaborative discussions focused on advancing personalized epilepsy treatment. The company’s participation reflects its ongoing commitment to expanding access to innovative neuromodulation therapies while supporting the physicians and care teams who deliver these treatments.
Advancing Responsive Neuromodulation in Epilepsy Care
As the field of epilepsy treatment continues to evolve, responsive neuromodulation is emerging as a powerful option for patients who do not achieve seizure control through medication alone. NeuroPace’s RNS System remains the first and only commercially available brain-responsive neurostimulation platform designed to monitor brain activity continuously and deliver targeted therapy directly to seizure-generating regions in real time.
At ASSFN 2026, NeuroPace will emphasize how long-term clinical evidence continues to support the effectiveness of responsive neuromodulation in reducing seizure frequency and improving quality of life for patients with drug-resistant epilepsy. The company will also highlight recent advancements that expand the potential reach of this technology beyond traditional focal epilepsy indications.
According to NeuroPace leadership, neurosurgeons play a critical role in broadening access to device-based therapies and helping patients benefit from emerging treatment innovations.
“Neurosurgeons are essential to expanding access to device-based therapy for drug-resistant epilepsy,” said Joel Becker, President and Chief Executive Officer of NeuroPace. “ASSFN provides an important opportunity to engage directly with physicians who are advancing the field, share practical experience with responsive neuromodulation, and support the education and training needed to bring personalized, data-informed therapy to more patients.”
Becker emphasized that as NeuroPace continues building clinical evidence across multiple epilepsy populations, including patients with idiopathic generalized epilepsy and other difficult-to-treat conditions, collaboration with neurosurgeons remains central to advancing patient care.
Spotlight on Thalamic Neuromodulation and the NAUTILUS Study
One of the highlights of NeuroPace’s ASSFN presence will be a scientific breakfast symposium focused on thalamic neuromodulation and emerging applications of responsive neurostimulation.
The session will be presented by Dr. Martha Morrell, Chief Medical Officer at NeuroPace and a recognized leader in epilepsy research and treatment. Scheduled for the morning of June 1, the symposium will explore the growing body of evidence supporting the use of responsive neuromodulation in a broader range of epilepsy syndromes.
A key topic will be findings from the NAUTILUS study, which investigates the use of the RNS System in patients with idiopathic generalized epilepsy (IGE). IGE represents a significant subset of epilepsy cases and is characterized by seizures that originate from widespread brain networks rather than a single focal region. Historically, treatment options for these patients have been limited, particularly when medications fail to provide adequate seizure control.
The symposium will examine how responsive neuromodulation targeting thalamic circuits may offer a promising therapeutic approach for this population. Researchers and clinicians attending the session will gain insight into how data from the NAUTILUS study is contributing to a deeper understanding of neuromodulation’s role in generalized epilepsy.
In addition to discussing IGE, the session will explore potential applications in other challenging neurological conditions, including Lennox-Gastaut syndrome, a severe form of epilepsy often associated with developmental and cognitive impairments. These discussions reflect growing interest within the epilepsy community in leveraging responsive neurostimulation across a wider spectrum of seizure disorders.
Supporting Physician Education and Surgical Training
Beyond scientific presentations, NeuroPace is actively supporting educational programming at ASSFN aimed at strengthening physician expertise in epilepsy surgery and neuromodulation therapies.
The company is participating in ASSFN Special Course 1, an educational session focused on epilepsy surgery fundamentals, patient selection, surgical approaches, and real-world clinical challenges. The course is designed to help neurosurgeons develop practical skills and knowledge necessary to evaluate and treat patients with drug-resistant epilepsy.
As awareness of neuromodulation therapies grows, educational initiatives play an increasingly important role in ensuring physicians can identify appropriate candidates and optimize treatment outcomes. NeuroPace views physician training as a critical component of expanding access to advanced epilepsy care.
By supporting educational programs, the company aims to equip healthcare professionals with the tools and knowledge needed to integrate innovative treatment options into clinical practice while maintaining high standards of patient care.
Showcasing AI-Enabled Clinical Decision Support
NeuroPace will also use the ASSFN meeting as a platform to introduce attendees to its latest technological innovations designed to improve clinical workflows and treatment planning.
At Booth #107 in the exhibit hall, visitors will have the opportunity to preview ECoG Assistant™, the company’s recently FDA-approved artificial intelligence-enabled tool. The software is designed to assist clinicians in reviewing electrocorticography (ECoG) data generated by the RNS System, helping healthcare providers identify meaningful patterns more efficiently and gain deeper insights into patient brain activity.
The increasing volume of neurological data generated through long-term monitoring presents both opportunities and challenges for clinicians. AI-powered tools such as ECoG Assistant aim to streamline data analysis, reduce review burden, and support more informed clinical decision-making.
By combining advanced analytics with responsive neurostimulation technology, NeuroPace seeks to further enhance personalized treatment strategies while improving workflow efficiency for epilepsy care teams.
Gathering Physician Feedback for Future Innovation
Throughout the conference, NeuroPace will conduct dedicated product feedback sessions with physicians and neurosurgical experts. These discussions are intended to provide valuable insights into current clinical needs, physician experiences, and opportunities for future innovation.
Company representatives will gather feedback on existing RNS System capabilities while also discussing next-generation product development initiatives. These conversations will help guide NeuroPace’s ongoing efforts to refine its technologies and address unmet needs in epilepsy treatment.
Members of the company’s executive leadership team will also meet individually with clinicians, researchers, and key opinion leaders to discuss emerging trends in epilepsy management, evolving treatment paradigms, and future directions for responsive neuromodulation.
The collaborative nature of these interactions reflects NeuroPace’s strategy of working closely with healthcare professionals to ensure that future innovations align with real-world clinical challenges and patient needs.
Engaging the Neurosurgical Community
During the five-day meeting, NeuroPace’s booth will serve as a central hub for discussions about epilepsy treatment, neuromodulation technologies, and patient support programs.
Attendees will have opportunities to participate in hands-on demonstrations of the RNS System and related tools, learn about patient identification resources, and explore educational materials designed to support long-term epilepsy management.
The company’s Patient Educator and Nurse Navigator teams will also be available to explain how NeuroPace supports patients and healthcare providers throughout the treatment journey. These services are designed to help individuals navigate therapy initiation, ongoing monitoring, and long-term care management.
By providing comprehensive support resources alongside innovative technology, NeuroPace aims to strengthen partnerships with healthcare providers while improving patient access to advanced treatment options.
Driving the Future of Personalized Brain Therapies
Headquartered in Mountain View, California, NeuroPace continues to focus on transforming the lives of individuals living with epilepsy through personalized, data-driven treatment approaches. The company’s RNS System represents a significant advancement in neuromodulation technology, delivering real-time therapy tailored to each patient’s unique brain activity patterns.
As research expands into new epilepsy populations and emerging neurological applications, NeuroPace believes responsive neurostimulation has the potential to redefine standards of care for patients who have limited treatment options.
At ASSFN 2026, the company’s scientific presentations, educational initiatives, AI innovations, and collaborative engagements will underscore its commitment to advancing the field of epilepsy care and supporting the next generation of personalized brain-responsive therapies.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
